The Haystead lab is part of Duke University School of Medicine's department of Pharamacology & Cancer biology. The Haystead laboratory has developed a unique chemical biology platform that enables all purine utilizing proteins (“the purinome”) to be interrogated against small molecule libraries en masse. The approach not only matches interesting molecules with their in vivo targets but also defines potential off target liabilities within the purinome. In this manner, we can advance molecules as tool compound to explore biological processes in vivo as well as potential begin new drug development programs. This approach was employed by the Durham (NC) based biotech company Serenex Inc. to develop SNX5422, a synthetic orally bioavailable inhibitor of Hsp90 currently in clinical development. Subsequently, we have employed a more advanced methodology (FLECS) to define novel inhibitors targeting DAP kinases, Pim kinases, fatty acid synthase, heat shock protein 70, TAK 1 kinase and IRAK 4 with indications in hypertension and cardiovascular remodeling, cancer and obesity, viral infections and inflammatory diseases respectively. Additionally, we have developed a small molecule tethering platform that enables protein targets to be imaged in vivo by a variety of methodologies including confocal microscopy (cell based studies), whole animal optical and nrIR imaging and PET for human studies.